Cited 0 times in
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2021-09-29T00:35:09Z | - |
dc.date.available | 2021-09-29T00:35:09Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183932 | - |
dc.description.abstract | High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10-5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Nature Pub. Group | - |
dc.relation.isPartOf | BLOOD CANCER JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal / administration & dosage | - |
dc.subject.MESH | Antibodies, Monoclonal / adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Chromosome Deletion* | - |
dc.subject.MESH | Chromosomes, Human | - |
dc.subject.MESH | Cytogenetic Analysis | - |
dc.subject.MESH | Dexamethasone / administration & dosage | - |
dc.subject.MESH | Dexamethasone / adverse effects | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lenalidomide / administration & dosage | - |
dc.subject.MESH | Lenalidomide / adverse effects | - |
dc.subject.MESH | Multiple Myeloma* / drug therapy | - |
dc.subject.MESH | Multiple Myeloma* / genetics | - |
dc.subject.MESH | Multiple Myeloma* / mortality | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Translocation, Genetic* | - |
dc.title | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jonathan L Kaufman | - |
dc.contributor.googleauthor | Meletios A Dimopoulos | - |
dc.contributor.googleauthor | Darrell White | - |
dc.contributor.googleauthor | Lotfi Benboubker | - |
dc.contributor.googleauthor | Gordon Cook | - |
dc.contributor.googleauthor | Merav Leiba | - |
dc.contributor.googleauthor | James Morton | - |
dc.contributor.googleauthor | P Joy Ho | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Naoki Takezako | - |
dc.contributor.googleauthor | Philippe Moreau | - |
dc.contributor.googleauthor | Heather J Sutherland | - |
dc.contributor.googleauthor | Hila Magen | - |
dc.contributor.googleauthor | Shinsuke Iida | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | H Miles Prince | - |
dc.contributor.googleauthor | Tara Cochrane | - |
dc.contributor.googleauthor | Albert Oriol | - |
dc.contributor.googleauthor | Nizar J Bahlis | - |
dc.contributor.googleauthor | Ajai Chari | - |
dc.contributor.googleauthor | Lisa O'Rourke | - |
dc.contributor.googleauthor | Sonali Trivedi | - |
dc.contributor.googleauthor | Tineke Casneuf | - |
dc.contributor.googleauthor | Maria Krevvata | - |
dc.contributor.googleauthor | Jon Ukropec | - |
dc.contributor.googleauthor | Rachel Kobos | - |
dc.contributor.googleauthor | Hervé Avet-Loiseau | - |
dc.contributor.googleauthor | Saad Z Usmani | - |
dc.contributor.googleauthor | Jesus San-Miguel | - |
dc.identifier.doi | 10.1038/s41408-020-00375-2 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00342 | - |
dc.identifier.eissn | 2044-5385 | - |
dc.identifier.pmid | 33149130 | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 111 | - |
dc.identifier.bibliographicCitation | BLOOD CANCER JOURNAL, Vol.10(11) : 111, 2020-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.